The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Aeglea BioTherapeutics | COM | 00773J103 | 26 | 6,000 | SH | SOLE | 6,000 | 0 | 0 | ||
Akari Therapeutics Plc | COM | 00972G108 | 1,115 | 158,352 | SH | SOLE | 158,352 | 0 | 0 | ||
Alcobra Ltd | COM | M2239P109 | 1,384 | 658,910 | SH | SOLE | 658,910 | 0 | 0 | ||
ARCA biopharma Inc | COM | 00211Y100 | 1,318 | 462,399 | SH | SOLE | 462,399 | 0 | 0 | ||
Ascendis Pharma A/S | COM | 04351P101 | 1,822 | 90,000 | SH | SOLE | 90,000 | 0 | 0 | ||
Adverum Biotechnologies | COM | 00773U108 | 3,198 | 1,102,735 | SH | SOLE | 1,102,735 | 0 | 0 | ||
Audentes Therapeutics | COM | 05070R104 | 274 | 15,000 | SH | SOLE | 15,000 | 0 | 0 | ||
Avadel Pharmaceuticals | COM | 338488109 | 5,195 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
Axovant Sciences Ltd | COM | G0750W104 | 2,287 | 184,110 | SH | SOLE | 184,110 | 0 | 0 | ||
BioCryst Pharmaceuticals Inc | COM | 09058V103 | 7,312 | 1,155,104 | SH | SOLE | 1,155,104 | 0 | 0 | ||
Coherus Biosciences Inc | COM | 19249H103 | 8,600 | 305,505 | SH | SOLE | 305,505 | 0 | 0 | ||
CoLucid Pharmaceuticals | COM | 19716T101 | 2,482 | 68,190 | SH | SOLE | 68,190 | 0 | 0 | ||
CytomX Therapeutics Inc | COM | 23284F105 | 706 | 64,200 | SH | SOLE | 64,200 | 0 | 0 | ||
DBV Technologies | COM | F2927N109 | 31,130 | 456,893 | SH | SOLE | 456,893 | 0 | 0 | ||
Edge Therapeutics Inc | COM | 279870109 | 1,688 | 135,000 | SH | SOLE | 135,000 | 0 | 0 | ||
Heron Therapeutics Inc | COM | 427746102 | 14,354 | 1,095,734 | SH | SOLE | 1,095,734 | 0 | 0 | ||
Lipocine Inc | COM | 53630X104 | 3,128 | 849,921 | SH | SOLE | 849,921 | 0 | 0 | ||
Ocera Therapeutics | COM | 67552A108 | 1,915 | 912,050 | SH | SOLE | 912,050 | 0 | 0 | ||
ProNAI Therapeutics Inc | COM | 74346L101 | 84 | 56,056 | SH | SOLE | 56,056 | 0 | 0 | ||
Ra Pharmaceuticals | COM | 74933V108 | 3,532 | 232,500 | SH | SOLE | 232,500 | 0 | 0 | ||
Stemline Therapeutics Inc | COM | 85858C107 | 1,449 | 135,420 | SH | SOLE | 135,420 | 0 | 0 |